liver cirrhosis

[POXEL SA] POXEL SA announced the completion of enrollment in DESTINY-1, a dose-ranging Phase II trial evaluating PXL065 for the treatment of non-alcoholic steatohepatitis (NASH).

[Scientific Reports] The authors examined the benefits of serum-free conditioned medium from stem cells derived from human exfoliated deciduous teeth on a murine non-alcoholic steatohepatitis (NASH) model induced by a combination of Western diet and repeated administration of low doses of carbon tetrachloride intraperitoneally, focusing on the gut-liver axis.

[Scientific Reports] Plasma markers of neutrophil extracellular traps formation were elevated in liver cirrhosis and correlated to the degree of liver dysfunction in patients with liver cirrhosis and/or hepatocellular carcinoma.

[Pharmaceutical Biology] In vitro, RAW264.7 cells were treated with lipopolysaccharides to induce macrophage polarization to the M1 phenotype, and they were co-cultured with WB-F344 cells and allocated to M group, YGJ group and WIF-1 group with untreated cells as control.

[Scientific Reports] New biochemical serum markers could be used to advance the diagnosis and prognosis of HBV-associated liver diseases during the progression of chronic hepatitis B into cirrhosis and hepatocellular carcinoma. Scientists determined whether the 4210 Da and 1866 Da polypeptides are serum metabolite biomarkers of hepatopathy with hepatitis B virus.

[Galecto, Inc.] Galecto, Inc. announced the treatment of the first patient in a Phase IIa trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis. The current standard of care for myelofibrosis is JAK inhibitors, but questions remain regarding side effects caused by the mechanism of action.